NCT05751642View on ClinicalTrials.gov

Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1920 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

April 19, 2023

Primary Completion Date

December 4, 2023

Study Completion Date

December 4, 2023

Conditions
Healthy Participants
Interventions
BIOLOGICAL

ALXN1920

Participants will receive a single dose of ALXN1920 by Subcutaneous (SC) injection.

BIOLOGICAL

Placebo

Participants will receive a single dose of Placebo by SC injection, SC infusion or IV infusion.

BIOLOGICAL

ALXN1920

Participants will receive a single dose of ALXN1920 by SC infusion.

BIOLOGICAL

ALXN1920

Participants will receive a single dose of ALXN1920 by Intravenous (IV) infusion.

Trial Locations (2)

1010

Clinical Trial Site, Grafton

8011

Research Site, Christchurch

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY